RegulatoryAug 12, 2026, 04:10 PM
Sangamo Therapeutics Reports June 2026 Operating Results in Bankruptcy
AI Summary
Sangamo Therapeutics, Inc. filed its Monthly Operating Report for June 2026, covering the initial period of its Chapter 11 bankruptcy, which commenced on June 23, 2026. The report indicates a net loss of $3.76 million for the period, with an ending cash balance of $14.38 million and total liabilities of $89.15 million. The company's stock has been delisted from Nasdaq and now trades on the OTCID Basic Market under 'SGMOQ', with a cautionary note to investors regarding the speculative nature of trading during bankruptcy.
Key Highlights
- Filed Chapter 11 bankruptcy on June 23, 2026.
- Ended June 2026 with $14.38M cash balance.
- Reported a net loss of $3.76M for the period.
- Total assets stood at $153.09M.
- Total liabilities were $89.15M.
- Prepetition unsecured debt totaled $78.13M.
- Current full-time employees: 73 (down from 74).
- Stock delisted from Nasdaq, now trades as SGMOQ.
Price Impact
More from SGMO